182 related articles for article (PubMed ID: 24116196)
1. XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer.
Qiu M; Xu L; Yang X; Ding X; Hu J; Jiang F; Xu L; Yin R
PLoS One; 2013; 8(10):e77005. PubMed ID: 24116196
[TBL] [Abstract][Full Text] [Related]
2. XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis.
Shen XY; Lu FZ; Wu Y; Zhao LT; Lin ZF
PLoS One; 2013; 8(8):e69553. PubMed ID: 23940523
[TBL] [Abstract][Full Text] [Related]
3. Predictive effect of XRCC3 Thr241Met polymorphism on platinum-based chemotherapy in lung cancer patients: meta-analysis.
Zhang W; Yan B; Jiang L
Tumour Biol; 2013 Dec; 34(6):3989-93. PubMed ID: 23990458
[TBL] [Abstract][Full Text] [Related]
4. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
[TBL] [Abstract][Full Text] [Related]
5. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
Xu C; Wang X; Zhang Y; Li L
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
[TBL] [Abstract][Full Text] [Related]
6. Association between XRCC3 Thr241Met polymorphism and colorectal cancer risk.
Wang Z; Zhang W
Tumour Biol; 2013 Jun; 34(3):1421-9. PubMed ID: 23504553
[TBL] [Abstract][Full Text] [Related]
7. Association between XRCC3 Thr241Met polymorphism and risk of brain tumors: a meta-analysis.
Liu J; Zhou Z; Lai T; Yin J
Tumour Biol; 2014 Feb; 35(2):1083-7. PubMed ID: 24061639
[TBL] [Abstract][Full Text] [Related]
8. DNA repair gene XRCC3 Thr241Met polymorphism and hepatocellular carcinoma risk.
Duan C; Zhang W; Lu J; Wu H; Liu M; Zhu W
Tumour Biol; 2013 Oct; 34(5):2827-34. PubMed ID: 23824570
[TBL] [Abstract][Full Text] [Related]
9. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
10. No significant association between the XRCC3 Thr241Met polymorphism and lung cancer risk: a meta-analysis.
Xu YH; Gu LP; Sun YJ; Cheng BJ; Lu S
Tumour Biol; 2013 Apr; 34(2):865-74. PubMed ID: 23300009
[TBL] [Abstract][Full Text] [Related]
11. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
12. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.
Li DJ; Xiao D
BMC Cancer; 2017 Jul; 17(1):501. PubMed ID: 28743242
[TBL] [Abstract][Full Text] [Related]
13. Association between the XRCC3 Thr241Met polymorphism and risk of colorectal cancer: a meta analysis of 5,193 cases and 6,645 controls.
Namazi A; Abedinzadeh M; Nourbaksh P; Neamatzadeh H
Asian Pac J Cancer Prev; 2015; 16(6):2263-8. PubMed ID: 25824748
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
Yu D; Shi J; Sun T; Du X; Liu L; Zhang X; Lu C; Tang X; Li M; Xiao L; Zhang Z; Yuan Q; Yang M
Tumour Biol; 2012 Jun; 33(3):877-84. PubMed ID: 22249976
[TBL] [Abstract][Full Text] [Related]
15. Association of XRCC3 Thr241Met polymorphism and leukemia risk: evidence from a meta-analysis.
Yan Y; Liang H; Li T; Guo S; Li M; Qin X; Li S
Leuk Lymphoma; 2014 Sep; 55(9):2130-4. PubMed ID: 24304418
[TBL] [Abstract][Full Text] [Related]
16. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
17. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
Xiang T; Kang X; Gong Z; Bai W; Chen C; Zhang W
Cancer Chemother Pharmacol; 2017 Apr; 79(4):791-800. PubMed ID: 28314991
[TBL] [Abstract][Full Text] [Related]
18. DNA repair gene XRCC3 Thr241Met polymorphisms and lung cancer risk: a meta-analysis.
Bei L; Xiao-Dong T; Yu-Fang G; Jian-Ping S; Zhao-Yu Y
Bull Cancer; 2015 Apr; 102(4):332-9. PubMed ID: 25794597
[TBL] [Abstract][Full Text] [Related]
19. Association between the XRCC3 C241T polymorphism and lung cancer risk in the Asian population.
Tian X; Tian Y; Ma P; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Jiang Y
Tumour Biol; 2013 Oct; 34(5):2589-97. PubMed ID: 23749486
[TBL] [Abstract][Full Text] [Related]
20. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
